New radiation technique aims to spare the urethra in prostate cancer treatment
NCT ID NCT05804318
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial is testing a daily adaptive radiation therapy for low to intermediate risk prostate cancer that spares the urethra. The goal is to reduce urinary side effects compared to standard radiation. About 132 participants will receive this tailored radiation, and their urinary quality of life will be tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daily adaptive stereotactic body radiation therapy (SBRT) with urethral sparing
What this could lead to
If successful, this approach could reduce urinary side effects during radiation for prostate cancer, making treatment more tolerable.
What could go wrong
This is an early-phase trial with no control group, so results may not confirm benefit. The approach is complex and may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
ACTIVE_NOT_RECRUITINGBoston, Massachusetts, 02115, United States
-
City of Hope Orange County Lennar Foundation Cancer Center
RECRUITINGIrvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Duarte Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fox Chase Cancer Center
ACTIVE_NOT_RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
-
Hospital Universitario de Navarra
RECRUITINGPamplona, Navarre, 31008, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikum der Landeshauptstadt Stuttgart gKAöR
RECRUITINGStuttgart, Baden-Wurttemberg, 70174, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsklinikum des Saarlandes (Saarland Univerisity Hospital)
RECRUITINGHomburg, Saarland, 66421, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University in St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••